22297 research outputs found
Sort by
Intracellular targeting of STIP1 inhibits human cancer cell line growth
Background: Extracellular and cell-surface molecules remain the most common druggable cancer targets. However, intracellular therapeutic modalities are gaining momentum. The overexpression of stress-induced phosphoprotein 1 (STIP1), an adaptor protein that coordinates the functions of different chaperones in protein folding, has been reported in several solid malignancies. Here, we investigated the effects of intracellular STIP1 inhibition, attained either through the HEPES-mediated cytosolic delivery of anti-STIP1 antibodies or the use of a cell-penetrating signal-tagged peptide 520, in different human cancer cell lines and luciferase-expressing murine ovarian cancer cells (MOSEC/Luc) tumor-bearing C57BL/6 mice.
Methods: The effects of STIP1 in different human cell lines were determined by cell viability, cell cytotoxicity and cell apoptosis assays. Immunoblotting was used to assess the relevant proteins found in this study and tumor xenograft mice models were also employed.
Results: Intracellular targeting of STIP1 inhibited cancer cell line growth and promoted caspase 3-dependent apoptotic cell death. Moreover, the intracellular delivery of anti-STIP1 antibodies facilitated the degradation of STIP1 and two of its client proteins, lysine-specific demethylase 1 and Janus kinase 2. In vivo studies demonstrated that survival of mice bearing experimental tumors was improved by administration of anti-STIP1 antibodies.
Conclusions: Our findings demonstrate that the cytosolic inhibition of STIP1 in tumor cells is feasible and provides a solid basis for further investigation of STIP1 as an intracellular cancer target. Our findings demonstrate that cytosolic inhibition of STIP1 in tumor cells is feasible and provide a solid basis for further exploration of STIP1 as an intracellular cancer target
Tailoring Health-promoting Programs for Patients with Chronic Kidney Disease: Randomized Controlled Trial
Research on dietary and lifestyle modifications to decrease cardiovascular risk and slow disease progression has been limited to patients in the later stages of chronic kidney disease (CKD). Studies on the effectiveness of stage-of-change-tailored interventions on lifestyle modifications for individuals with early stage CKD are limited. Using random assignment, 60 patients with early stage CKD who received up to six tailored intervention visits over 30 months were compared to 60 usual care patients on physical indicators, lifestyle behaviors, and quality of life. Tailored interventions were consistent with the trans-theoretical Model of Change. Waist circumference, nutrition, and stress management improved over time in the intervention group. There was no difference or change in quality of life. To promote a healthier lifestyle, findings suggest that clinicians working with patients with CKD should consider patients' readiness to change their behaviors as well as implementation strategies tailored for different processes of change
To evaluate the transitions care from hospital discharge planning to the community-based long-term services
The relationships of Successful Smoking Cessation and Health Belief, Self-efficacy and Quality of Life in Patients with Acute Myocardial Infarction:A Preliminary study
指導教授:張曉雲研究背景:心臟疾病從92年起占國人主要死亡原因第二位,而心血管疾病的導因中有10%來自吸菸,是繼高血壓後的第二大原因。戒菸與個人自我效能及健康信念有密切關係,因此,本研究以急性心肌梗塞病人為對象,了解其自我效能、健康信念及生活滿意度之關係,強化戒菸動機以提升戒菸成效。
研究目的:本研究以醫院急性心肌梗塞病人就醫後一年於心臟內科門診就診為對象,探討急性心肌梗塞病人之戒菸成功與自我效能、健康信念及生活滿意度之相關性。
研究方法:以結構式問卷為研究工具,以心臟內科門診待診區為研究場所,針對回診個案進行取樣,在研究場所詢問收案對象,其必須符合收案條件,有意願填寫問卷的個案,由施測者帶至門診衛教室給予填寫問卷。
研究結果:共收集148位個案,全部為男性,平均年齡58.25歲,收集個案中戒菸大於一年有77人(52.7%)、未戒菸者71人(47.3%)。進一步分析個案實際抽菸年數 (t = 2.69, p = 0.008)、健康信念( t =-3.34, p = 0.001)、自覺罹患性(t = -3.07, p = 0.003)、自覺嚴重性(t = -5.64, p = <0.001)、自覺利益性(t = -6.57, p =<0.001)、自覺障礙性(t = 9.06, p = <0.001)、自我效能(t = -25.22, p = <0.001)達統計上顯著性差異達。經進行逐步迴歸分析(stepwise regression)自我效能、高齡、實際抽菸年數少、自覺嚴重性、自覺利益性、自覺障礙性為急性心肌梗塞吸菸病人戒菸成功因素,將研究結果做為執行戒菸衛教時的參考依據,期盼提升急性心肌梗塞病人戒菸成功比率